Cryo-Cell International, Inc., the pioneer private cord blood bank, maintains a robust specimen base but faces substantial challenges from arbitration with Duke University following a key license termination. Its traditional cellular processing and storage segments continue as cash flow drivers, yet FY2025 saw sharply reduced operating income and expanded net losses amid investments and legal costs. Liquidity is constrained with cash under $250K as of early 2026, prompting reliance on credit facilities. Near-term growth depends on resolving legal disputes and advancing new service initiatives.